Our economic analysis of professional CGM using real-world data was published in the Journal of Medical Economics. With this analysis, Medtronic Diabetes is the first to demonstrate the significant clinical and health economic benefits of professional CGM products – such as iPro™2 – for people living with type 2 diabetes, and healthcare systems. Prior
This article is based on an interview with Dr. Edward Dick, MD, Medical Director at Methodist Healthcare Ministries of South Texas, Inc on the Medtronic Turning Point program. As Medical Director of Methodist Healthcare Ministries, Dr. Edward Dick, MD, sees the impact type 2 diabetes has on patients in his Southern Texas community. The
Today we announced a partnership with Fitbit to integrate health and activity data into new CGM solutions for simplified type 2 diabetes management. This partnership brings together our sophisticated medical technology with the convenience of automatic activity tracking from Fitbit. Together we can provide meaningful insights into how exercise impacts glucose levels for more
Our industry is changing and evolving at an unprecedented rate, which is why it is important for us to set the pace of innovation across several areas. Disruptive Innovation for Type 1 Diabetes Recently, we shared pivotal trial results for the first hybrid closed loop system. I am extremely excited to announce today that
I am very excited to share with you that we are collaborating with Qualcomm Life to develop future-generation continuous glucose monitoring (CGM) systems for people with type 2 diabetes. This collaboration – with an expert in developing reference designs for wireless, single-use and small integrated modules – enables us to create more affordable, easier-to-use
Imagine you are a pilot flying at thirty thousand feet. The cloud layer is so thick, you cannot see more than 40 feet ahead of you. In addition, your gauges and computers are down. Other than a few cloud breaks now and then, you are flying blind. You have just experienced what it is
I am excited to announce Diabetes, Obesity and Metabolism, an international, peer-reviewed journal, recently published the results of the continuation phase of our OpT2mise study, which could redefine the standard of care and expand access to insulin pump therapy for the growing population of insulin-dependent people with type 2 diabetes with poor glucose control.